SCHEMBL4496544

SCHEMBL4496544

Cc1cccc(C)c1-c1ccc2c(N)n[nH]c2c1

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PDPK1 O15530 17/20 0.64
JAK2 O60674 3/20 0.63
TGFBR1 P36897 7/20 0.56
AURKA O14965 6/20 0.56
AURKB Q96GD4 6/20 0.56
ROCK1 Q13464 4/20 0.56
GRIA1 P42261 1/20 0.53
CACNG8 Q8WXS5 1/20 0.53
CHUK O15111 1/20 0.50
RPS6KB1 P23443 1/20 0.50
CDK2 P24941 1/20 0.50
KDR P35968 1/20 0.50
SYK P43405 1/20 0.50
JAK3 P52333 1/20 0.50
MAP3K5 Q99683 1/20 0.50
KDM4E B2RXH2 1/20 0.47
CYP3A4 P08684 1/20 0.47
GAA P10253 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13525177 0.85 PDPK1 (0.55) PDPK1JAK2TGFBR1AURKAAURKB
SCHEMBL12907205 0.84 JAK2 (0.64) PDPK1JAK2TGFBR1AURKAAURKB
SCHEMBL4491663 0.82 PDPK1 (0.71) PDPK1JAK2TGFBR1AURKAAURKB
SCHEMBL6479941 0.79 JAK2 (0.72) PDPK1JAK2TGFBR1AURKAAURKB
SCHEMBL13986221 0.78 PDPK1 (0.66) PDPK1JAK2TGFBR1AURKAAURKB
SCHEMBL12907253 0.78 PDPK1 (1.00) PDPK1JAK2TGFBR1AURKAAURKB
SCHEMBL13525278 0.78 JAK2 (0.59) PDPK1JAK2TGFBR1AURKAAURKB
SCHEMBL3361070 0.77 JAK2 (1.00) PDPK1JAK2TGFBR1AURKAAURKB
SCHEMBL12907241 0.77 JAK2 (1.00) PDPK1JAK2TGFBR1AURKAAURKB
SCHEMBL4482791 0.76 JAK2 (0.54) PDPK1JAK2TGFBR1AURKAAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1506176-B1 AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM PFIZER ITALIA SRL (IT) 2013-04-24 EP disclosed
US-7632854-B2 Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PFIZER ITALIA S.R.L. (IT) 2009-12-15 US disclosed
US-20060106083-A1 Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PHARMACIA ITALIA S.P.A. (IT) 2006-05-18 US disclosed
EP-1506176-A1 AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM Pharmacia Italia S.p.A. (IT) 2005-02-16 EP disclosed
WO-2003097610-A1 AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM PHARMACIA ITALIA S.P.A. (IT) 2003-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060106083-A1 Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them MAP3K15, MAP3K3, MAP3K20 PDPK1 34/4885JAK2 416/4885TGFBR1 3331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.